Optima has delivered a filling system to Catalent‘s biologics facility in Bloomington, IN, US. The vial system with an isolator is the second vial line to be installed at the site and will be used initially for the filling of a vaccine candidate to fight covid-19 (SARS-CoV-2).
The first partial shipment to the US was at the beginning of August. An Antonov An-124 cargo aircraft was chartered for transportation.
Catalent is investing US$50 million (£38 million) to install a third high-speed vial filling line, which is expected to be operational by April 2021 and has capacity to produce up to 80 million vials annually under barrier isolator technology and a peristaltic pump filling mechanism, consistent with cGMP. The company said that by the end of 2021 the site would have high-speed filling capacity across three vial lines, two syringe lines, and a flexible line capable of filling vials, syringes, or cartridges. The facility has expertise in sterile formulation, with drug substance development and manufacturing and drug product fill-finish capacity, including primary and secondary packaging.
Link to Optima Press Release
Link to Catalent Press Release
Previous article
INNOVATION AND AUTOMATION IN TOPICAL FORMULATION DEVELOPMENTNext article
TECHNOLOGY SHOWCASE: CCBio’s QuickDose